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RESULTS
Limitations
 Small sample size 
 Lack of documentation of antipsychotic indication 
 Inconsistent documentation or administration of CAM-ICU 
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Conclusions
 Antipsychotic-naïve patients who are initiated on an antipsychotic in 
the ICU are continued on the agent at a rate of 49% at hospital 
discharge 
 Antipsychotics initiated in the ICU are continued in the step-down 
units at a rate of 82%
 Quetiapine is the most commonly prescribed antipsychotic agent in 
the ICU 
 Patients prescribed antipsychotic agents in the ICU are commonly on 
prolonged courses of sedation. On average, antipsychotics are 
started on day 8 of ICU admission
 Longer ICU length of stay was associated with a higher likelihood of 
antipsychotic discontinuation prior to discharge
 Patients were most commonly initiated on quetiapine at a total daily 
dose of 25 mg or 50 mg and titrated up to 50 mg or 100 mg 
respectively 
 Antipsychotic initiation and discontinuation was not associated with 
CAM-ICU scores
 CAM-ICU scores were documented in 83% of patients however all 
results were either “negative” or “unable to assess”
 Justification for inability to assess CAM-ICU scores included barriers 
to communication and high levels of sedation
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Background
 Delirium is common in the critically ill with a prevalence of up to 80% in 
mechanically ventilated patients in the Intensive Care Unit (ICU)1,2
 ICU related delirium is a clinical diagnosis made based on screening 
tools such as the Confusion Assessment Method for the ICU (CAM-ICU)3
 Risk factors for delirium occurrence include benzodiazepine use, age, 
dementia, emergency surgery or trauma, and increasing severity of 
illness3
 The 2018 PADIS Guidelines published by the Society of Critical Care 
Medicine recommend against the routine use of both typical and 
atypical antipsychotic agents for either the prevention or treatment of 
delirium. Non-pharmacological strategies are preferred3
 Evidence suggests that the use of antipsychotics in patients with 
delirium is not associated with a shorter duration of delirium, 
mechanical ventilation or ICU length of stay. Antipsychotic use is also 
not associated with decreased mortality3
 Antipsychotics, when ordered in the ICU, are commonly inappropriately 
continued post transfer from the ICU and following discharge from the 
hospital3,4,5,6
 Many undesirable side effects accompany long-term use of 
antipsychotics such as weight gain, hyperlipidemia, QTc prolongation, 
extrapyramidal symptoms (EPS), and increased mortality in elderly 
patients with dementia related psychosis7
Methods
 Study design: Single-center, retrospective chart review of anti-psychotic 
naïve patients admitted to the ICU at Baptist Hospital of Miami and 
initiated on an antipsychotic between June 1, 2018 and July 1, 2019
 Inclusion criteria: Individuals ≥ 18 years old, patients initiated on a new-
start antipsychotic in the ICU receiving at least 2 days of therapy
 Exclusion criteria: Patients ordered “as needed” or one-time 
antipsychotics, patients on antipsychotic prior to hospitalization or ICU 
admission, patients who did not survive to discharge, pregnant patients 
 Primary outcome: Percentage of patients prescribed a new-start 
antipsychotic in the ICU that was continued post-hospital discharge 
based on the discharge medication reconciliation and discharge 
summary 
 Secondary outcomes: Percentage of patients prescribed a new-start, 
standing antipsychotic in the ICU that was continued post-ICU discharge
 Antipsychotic agent, regimen, and duration 
 CAM-ICU administration, documentation, and result  
Objectives
 Determine the incidence of antipsychotic initiation in the ICU for 
delirium prevention or treatment at Baptist Hospital of Miami 
including the agent, dose, frequency, and duration of therapy  
 Determine the rate of continuation of newly initiated antipsychotics 
following discharge from both the ICU and hospital
 Evaluate the use and documentation of CAM-ICU scores as a tool for 
initiating and discontinuing antipsychotic therapy appropriately 
 Establish the foundation for the development of a pharmacist-driven 
protocol to aid in the discontinuation of antipsychotic agents when 
used for ICU-related delirium8
Confusion Assessment Method for the ICU (CAM-ICU)
1. Acute onset or fluctuating course compared to baseline or within the last 24 hours 
2. Inattention (letters attention test)
3. Altered level of consciousness (Richmond Agitation-Sedation Scale) 
4. Disorganized thinking 
Delirium diagnosis if 1 and 2 are present with either 3 or 4. CAM-ICU should be reassessed at another time if RASS <-3
Baseline Characteristics N=76
Mean age, years 67
Gender - male, n (%) 56 (74)
Antipsychotic, n (%):
Quetiapine
Risperidone
Olanzapine
67 (88)
5 (7)
4 (5)
14 (18%)
37 (49%)
Discharge location of 
patients continued on 
antipsychotic 
n=37
Skilled nursing facility 13
Home 8
Acute inpatient rehab 5
Home with services 4
Long term acute care 2
Rehab 2
Subacute rehab 1
Psychiatric unit 1
Transfer 1
Timing of Therapy and Length of Stay
Overall 
population 
N=76
Discontinued 
in ICU
n=14
Discontinued
in step down 
n=25
Continued post 
hospital discharge 
n=37
Mean ICU day of anti-
psychotic initiation
ICU day 8.2 ICU day 10.0 ICU day 8.0 ICU day 7.5
Mean ICU LOS (days) 12.9 17.8 11.7 11.9
Mean duration of 
antipsychotic therapy 
(days)
12.0 (1-51) 5.5 10.8 15.2
Mean duration of 
sedation/opioid 
(days)
6.0 7.0 6.0 6.0
Mean duration of 
intubation (days)
7.0 9.9 6.0 6.4
CAM-ICU N=76
Patients with at least one 
documented positive CAM-ICU 
score, n (%)
0 (0)
Number of patients with no 
documented CAM-ICU score, 
n (%)
13 (17)
Number of patients “unable to 
assess”, n (%)
7 (9)
Number of patients with at least 
one negative documented CAM-
ICU score, n (%)
56 (74)
Reason for unable to assess
“Non-English speaking”
“RASS -4/-5”
“Extremely hard of hearing”
“Refused”
“Severe mental disability”
“Blind”
Quetiapine Regimen n=67
Initial daily dose, n (%):
12.5 mg
25 mg
50 mg
100 mg
7 (10)
26 (39)
28 (42)
6 (9%)
Maximum daily dose, n (%):
12.5 mg
25 mg
37.5 mg
50 mg 
75 mg
100 mg
125 mg 
150 mg 
200 mg
450 mg
5 (8)
16 (24)
1 (2)
25 (37)
1 (2)
14 (21)
1 (2)
2 (3)
1 (2)
1 (2)
Future Implications
 Opportunity for education regarding the appropriate documentation 
and utility of CAM-ICU scores
 Potential implementation of a pharmacist-driven protocol to ensure 
patients are not discharged inappropriately on antipsychotic therapy 
Antipsychotic Prescribing Trends
Discontinued in the ICU 
Discontinued in step-down unit
Continued post hospital discharge
25 (33%)
